Development status: Approved, off-patent, not available in many countries

Gram-positive activity

Mechanism of Action/Target pathogen: Binds to the rRNA of the bacterial 50S ribosome subunit, overlapping with the binding sites of the oxazolidinone, pleuromutilin, and macrolide antibiotics, thus blocking ribosomal translocation. Bacteriostatic activity.

Additional information: Natural product produced by Streptomyces. Parenteral application.